[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"meningoccocal-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:meningoccocal-disease":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":24,"studyType":25,"phases":4,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100622094","evaluation-of-the-antibody-persistence-beyond-five-years-after-immunization-with-menfivetm-nmcv-5-a-pentavalent-meningococcal-acywx-conjugate-vaccine-100622094",false,"NCT07379151","Evaluation of the Antibody Persistence Beyond Five Years After Immunization With MenFiveTM (NmCV-5), a Pentavalent Meningococcal ACYWX Conjugate Vaccine","Evaluation of the Antibody Persistence in African Participants Beyond Five Years After Immunization With MenFiveTM (NmCV-5), a Pentavalent Meningococcal ACYWX Conjugate Vaccine","PERS-ACYWX-03","Inclusion Criteria:\n\n* Written informed consent and assent (if applicable)\n\nExclusion Criteria:\n\n* Current or previous, confirmed disease caused by Neisseria meningitidis at any given time since meningococcal vaccination\n* Any condition or criteria that in the opinion of the investigator might compromise the well-being of the participant or the compliance with study procedures or interfere with the outcome of the study",true,"ALL","7 Years","36 Years",{"count":22,"type":23},450,"ESTIMATED","1 Day","OBSERVATIONAL","This study will measure immune persistence of the NmCV-5 more than 5 years after a single dose vaccination in participants 2-29 years of age in Mali and The Gambia.",[28],"Meningoccocal Disease",[30,31],"Seropersistence","Meningococcal","RECRUITING","2026-05-29",{"date":35,"type":36},"2026-06-03","ACTUAL",{"date":38,"type":36},"2026-05-05",{"date":40,"type":23},"2026-12",{"name":42,"class":43},"Serum Institute of India Pvt. Ltd.","INDUSTRY",2]